Certain human leukocyte antigens may increase the risk of cytomegalovirus interstitial pneumonitis, an important complication of bone marrow transplantation. The prevalence of this pneumonitis was compared between patients possessing either HLA-B51 or HLA-B52 and patients without either antigen. The role of tumor necrosis factor-␣ in cytomegalovirus interstitial pneumonitis was also studied. Among 72 patients undergoing allogeneic bone marrow transplantation at our institution during the past 5 years, HLA-B51 or -B52 was detected in 29. Among these 29 patients, 13 (45%) developed cytomegalovirus interstitial pneumonitis, a significantly higher rate (P Ͻ 0.001) than among patients without these HLA types (4/43, 9%). In the preconditioning and stable phases, tumor necrosis factor-␣ levels were higher in patients with HLA-B51 or HLA-B52 than in patients without (P Ͻ 0.05; t-test). Throughout the period from pre-conditioning to around day 40, except on day 0, tumor necrosis factor-␣ levels were also significantly higher (P Ͻ 0.05 to P Ͻ 0.001) in patients developing cytomegalovirus infection than in those without it. These results suggest that HLA-B51 and HLA-B52 may be risk factors for cytomegalovirus interstitial pneumonitis after bone marrow transplantation, with an increase of tumor necrosis factor-␣ also being involved. Bone Marrow Transplantation (2000) 25, 861-865. Keywords: cytomegalovirus interstitial pneumonitis; human leukocyte antigen; bone marrow transplantation; tumor necrosis factor-␣ Cytomegalovirus interstitial pneumonitis (CMV-IP) is a very important and common complication of bone marrow transplantation (BMT), which can influence the outcome of this procedure. There have been many reports on the risk factors, preventive measures, and treatment of CMV-IP.
which an association with CMV-IP has not yet been reported. The frequency of HLA-B51 is significantly increased in patients with Behçet's disease, 5 and the same is true for HLA-B52. 6 Neutrophil dysfunction, 5, 7 immunological abnormalities, 7, 8 and microvascular inflammation, 9, 10 caused by an increase of tumor necrosis factor (TNF)-␣ are generally accepted to occur in Behçet's disease. In the present study, the influence of HLA-B51 and HLA-B52 was assessed in patients with CMV-IP diagnosed at our institution over the past 5 years since the establishment of preventative therapy for this disease. In addition, changes of the TNF-␣ level were studied in an attempt to clarify the role of this cytokine in CMV-IP.
Materials and methods

Patients
The subjects were 72 consecutive patients who were seropositive for CMV or whose donors were seropositive and who underwent allogeneic BMT at our department between April 1994 and March 1999. Before bone marrow transplantation, all patients were in good condition without any signs of infection.
HLA typing
A serological method was used for HLA typing. Two controls were provided for each of the 72 patients and comparisons were made between the patients and these 144 controls.
CMV prophylaxis
We administered acyclovir (250 mg three times daily) from day Ϫ7 to approximately day 30 after BMT. All patients received 12.5 g of immunoglobulin with a high titer of anti-CMV antibodies biweekly until 3 months after transplantation. To detect CMV infection, both the bronchoalveolar lavage fluid (BALF) and peripheral blood (PB) were checked for CMV-DNA approximately 35 days after BMT 11 using the polymerase chain reaction (PCR) method since 1992. The direct immunoperoxidase method was also used for CMV antigen screening, since 1998, employing a peroxidase-labelled monoclonal antibody for matrix protein p65 of CMV (HRP-C7). 12 The HRP-C7 method was used for CMV antigen screening of BALF on day 35, and for screening of PB once weekly until day 50 and then biweekly to monthly depending on the clinical manifestations until day 100. If either PB or BALF was positive for CMV by at least one of these methods, ganciclovir was administered according to the schedule of Singhal et al 13 (5 mg/kg twice daily in week 1 and once daily in weeks 2 and 3). Then the dose was adjusted depending on the CMV-DNA level and the C7-HRP HRP antigen level in PB samples, as well as the extent of myelosuppression in weeks 2 and 3.
Diagnosis of CMV-IP
CMV-IP was diagnosed by the following five criteria: (1) symptoms of fever, nonproductive cough, and tachypnea; (2) hypoxia; (3) radiological findings suggestive of interstitial pneumonitis; (4) detection of CMV-DNA or CMV antigen as described above; and (5) no evidence for another cause of pneumonitis.
Conditioning regimen and GVHD prophylaxis
The conditioning regimen was busulfan (BU) ϩ cyclophosphamide (CY) ϩ total body irradiation (TBI) (BU at a dose of 4 mg/kg/day ϫ 2 days, CY at 30 mg/kg/ day ϫ 2 days, and TBI at 3 Gy ϫ 4) for the high-risk group, or BU ϩ CY (BU at 4 mg/kg/day ϫ 4 days and CY at 60 mg/kg/day ϫ 2 days) for the standard-risk group. For GVHD prophylaxis, the basic treatment was CsA ϩ methotrexate ϩ methylprednisolone or CsA ϩ methotrexate.
Assay of TNF-␣
TNF-␣ was investigated in the latest 51 consecutive patients (18 with HLA-B51 or -B52 and 33 with other HLA types) who underwent allogeneic BMT at our department between January 1996 and March 1999. The TNF-␣ level was determined on six occasions: (1) before conditioning; (2) day 0 of BMT (before bone marrow infusion); (3) during the aplastic phase (day 5-10); (4) at the time of rapid leukocyte recovery; (5) at the time of stabilization of the WBC after discontinuation of granulocyte colony-stimulating factor (day 21-28); and (6) around day 40 following BMT. Blood samples were collected into tubes containing 3.8% citric acid at a ratio of 1:9. After separation by centrifugation at 1500 g for 10 min at 4°C, plasma was stored at Ϫ80°C. TNF-␣ was measured twice at each specified time using an ELISA kit from Endogen (Woburn, MA, USA) and the mean value was determined.
Statistical analysis
Statistical analysis was done using the t-test and Fisher's exact probability test, and P Ͻ 0.05 was considered to indicate a significant difference.
Results
The clinical characteristics of the patients are shown in Table 1 , including the age, sex, underlying disease, disease stage, donor type, conditioning regimen, and GVHD prophylaxis. The patients with HLA-B51 or HLA-B52 did not differ significantly from the patients without these HLA types. Out of 144 casess, 15 (10%) had HLA-B51 and 14 (10%) had HLA-B52, rates that were similar to the mean reported values. The number of patients with a diagnosis of CMV-IP and the number with reactivation of CMV infection in both groups is shown in Table 2 . IP developed in 17 (25%) of the 72 patients, a higher incidence than reported by other researchers. Fifteen of these 17 patients developed CMV-IP before 1997. After the start of frequent peripheral blood examination for CMV antigen by the C7-HRP method combined with prophylactic administration of ganciclovir, it only occurred in two patients. Patients possessing HLA-B51 or HLA-B52 were significantly more likely to develop CMV-IP than those with other HLA types. CMV underwent reactivation in 16 (55%) of the 29 patients who had HLA-B51 or HLA-B52. This rate was higher than in the patients with other HLA types (17/43 patients, 40%), but the difference was not statistically significant (P = 0.23; Fisher's exact probability test). In the B51/52 group, how- ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; SAA = severe aplastic anemia; ML = mixed leukemia; LBL = lymphoblastic lymphoma; CR1/2 = complete remission 1st/2nd; NR = no remission; CP = chronic phase; AP = accerelated phase; R = related; UR = unrelated; BU = busulphan; CY = cyclophosphamide; TBI = total body irradiation; TLI = total lymph node irradiation; CsA = cyclosporin; MTX = methotrexate; mPSL = methylprednisolone. ever, IP developed in 13 (81%) of the 16 patients with reactivation of CMV infection. This rate was significantly higher than that in the other patients (4/17, 24%) (P Ͻ 0.01: Fisher's exact probability test). The TNF-␣ levels in these two groups of patients are shown in Figure 1 . During the pre-conditioning phase and the stable phase, the TNF-␣ level was significantly higher in patients with HLA-B51 or HLA-B52 than in patients with other HLA types (P Ͻ 005; t-test). The TNF-␣ level in patients developing CMV-IP was compared with that in patients without CMV-IP ( Figure 2 ). Throughout the period from preconditioning to around day 40, except on day 0, the TNF-␣ level was significantly higher (P Ͻ 0.05) in the patients who developed CMV-IP. Around day 40, the TNF-␣ level was normalized in all patients who did not develop CMV-IP, but it was still significantly above normal in those who developed CMV-IP (P Ͻ 0.001). This difference was greater than the overall difference between patients with and without CMV-IP. Only one of the 17 patients had developed CMV-IP by day 40 and the onset was later in the remaining 16 patients. There was elevation of TNF-␣ before the onset of CMV-IP in almost all patients. 
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Discussion
Grundy and colleagues 14 suggested that the presence of CMV is essential for the development of CMV-IP, but that the virus is not the direct cause. Tanaka et al 15 confirmed this hypothesis by showing that the direct cause of CMV-IP is cytokines such as TNF-␣ and IFN-␥. The mechanism by which CMV infection leads to CMV-IP is thought to be as follows: the lungs are the site of virus entry and also a site for the production of cytokines such as TNF-␣. 16 Thus, the stimulation of TNF-␣ production by CMV may lead to an increase of various cytokines and mediators, resulting in CMV-IP. The present study showed that patients with HLA-B51 or HLA-B52 had a significantly higher risk of CMV-IP than those without these HLA types. In addition, the TNF-␣ level was significantly higher before conditioning in patients with HLA-B51 or HLA-B52, and it rose further around day 40 after BMT in the patients who eventually developed CMV-IP when compared with those who did not. The proximity of the B51 or B52 gene in the MHC class I locus with the TNF gene in the class III locus causes linkage disequilibrium of their alleles, which may be one reason for this relationship. An association of TNF-␣ and other cytokines with CMV disease has been described by several authors. [17] [18] [19] [20] [21] Our results also suggested that either HLA-B51 or -B52 had a role in the increase of TNF-␣, indicating that CMV-IP may develop when TNF-␣ stimulates the production of various other cytokines. As described above, the incidence of CMV-IP after reactivation of CMV was significantly higher in patients with HLA-B51 or HLA-B52 than in patients with other HLA types, although the frequency of CMV reactivation was almost the same in these two groups. This also suggests a role for TNF-␣ and other cytokines in the pathogenesis of CMV-IP. Furthermore, the TNF-␣ level around day 40 after BMT seems likely to be a useful predictor of the risk of CMV-IP.
In summary, we demonstrated that patients with HLA- B51 or HLA-B52 have a significantly greater risk of developing CMV-IP than patients with other HLA types. The possible mechanism underlying this association is that HLA-B51 and HLA-B52 may enhance the production of TNF-␣, with the various cytokines stimulated as a result, as well as the increase of TNF-␣ itself, giving rise to CMV-IP.
